Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study

Description

This trial collects clinical data and blood samples to predict the quality of response to specific treatments in patients with chronic graft-versus-host disease (cGVHD) who are about to start a new therapy. Collecting and analyzing clinical data and blood samples from patients with cGVHD before and after treatment initiation may help doctors identify changes that may predict treatment response.

Conditions

Chronic Graft Versus Host Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

This trial collects clinical data and blood samples to predict the quality of response to specific treatments in patients with chronic graft-versus-host disease (cGVHD) who are about to start a new therapy. Collecting and analyzing clinical data and blood samples from patients with cGVHD before and after treatment initiation may help doctors identify changes that may predict treatment response.

Predicting the Quality of Response to Specific Treatments (PQRST)

Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study

Condition
Chronic Graft Versus Host Disease
Intervention / Treatment

-

Contacts and Locations

Gainesville

University of Florida, Gainesville, Florida, United States, 32610

Tampa

Moffitt Cancer Center, Tampa, Florida, United States, 33612

Boston

Dana-Farber Harvard Cancer Center, Boston, Massachusetts, United States, 02115

Minneapolis

University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States, 55455

Buffalo

Roswell Park Cancer Institute, Buffalo, New York, United States, 14263

Cleveland

Cleveland Clinic Foundation, Cleveland, Ohio, United States, 44195

Pittsburgh

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States, 15232

Nashville

Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States, 37232

Seattle

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States, 98109

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adults age 18 or older
  • * Prior allogeneic stem cell transplant, with any graft source, donor type, and GVHD prophylaxis
  • * No evidence of persistent or progressive malignancy at the time of enrollment
  • * Agrees to be evaluated at the transplant center before a new line of treatment is started (may be concurrent with the enrollment visit), and later between 2-6 weeks, 3 months and 6 months after index treatment is started or if an additional new therapy is started before 6 months
  • * Signed, informed consent
  • * Inability to comply with study procedures
  • * Uncontrolled psychiatric disorder
  • * Anticipated survival \< 6 months

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Fred Hutchinson Cancer Center,

Stephanie J. Lee, PRINCIPAL_INVESTIGATOR, Fred Hutch/University of Washington Cancer Consortium

Study Record Dates

2026-08-02